Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
Medtronic has launched the Neurovascular Co-Lab™ Platform to enhance collaboration among start-ups, physicians, and institutions for stroke care innovation. This initiative aims to expedite the development of advanced technologies to benefit stroke patients globally. The platform will be operational by World Stroke Day, October 29, 2022, and is designed to facilitate the submission and funding of high-potential neurovascular innovations. Medtronic highlights the urgent need for improved stroke treatments, noting that millions remain untreated despite the availability of therapies.
Medtronic plc (NYSE:MDT) will participate in the CECP's 10th CEO Investor Forum at AdvaMed's 2022 MedTech Conference on October 25, 2022, in Boston, MA. CEO Geoff Martha will present at 3:30 p.m. CDT and answer questions.
A live webcast will be available on the same day via the Investor Events link on Medtronic's investor relations page, with a replay accessible within 24-48 hours.
Medtronic is a global leader in healthcare technology, dedicated to alleviating pain and restoring health through innovative solutions.
Medtronic plc (NYSE:MDT) has announced plans to separate its Patient Monitoring and Respiratory Interventions businesses into a new entity, referred to as NewCo. This strategic move aims to enhance operational focus and drive value creation for stakeholders. The separation is expected to be tax-free for U.S. shareholders and is anticipated to complete within 12 to 18 months, subject to regulatory approvals. NewCo will provide connected care solutions, leveraging its strong commercial footprint and wide-ranging product portfolio, which generated approximately $2.2 billion in revenue in fiscal 2022.
Medtronic (NYSE:MDT) announced significant approvals for its Hugo™ robotic-assisted surgery system, enhancing its market presence globally. The approvals include CE Mark clearance for general surgery in the EU, a license for laparoscopic surgery in Canada, and MHLW approval for urologic and gynecologic laparoscopic procedures in Japan. These milestones position Medtronic to access key markets, particularly in Japan, the third-largest robotic surgery market, and capitalize on the growth of minimally invasive procedures, which account for over 80% of global RAS procedures.
Medtronic plc has launched a groundbreaking program called My Insights for users of the MiniMed™ 770G system, utilizing data science to deliver personalized diabetes management tips and trends. This is the first program offering tailored insights based on individual user data, enhancing diabetes care with monthly educational emails. The MiniMed 770G system, known for its automated insulin adjustments and smartphone connectivity, supports users aged two and above. Medtronic aims to simplify diabetes management and empower users with customized tools.
Medtronic has received FDA approval for its SelectSecure Model 3830 cardiac lead to include left bundle branch area pacing, enhancing its conduction system pacing capabilities for patients with bradycardia. This innovative method mimics natural heart contraction, reducing complications associated with traditional pacing. The approval is based on evidence from over 20,000 patients, demonstrating a 92% procedural success rate and a low complication rate of 2.5%. Medtronic remains the only company with FDA-approved therapies for conduction system pacing, further solidifying its leading position in cardiac pacing technologies.
Medtronic plc (NYSE:MDT) announced a live webcast on November 7, 2022, at 5 p.m. CST, to discuss updates on its Coronary and Renal Denervation business during AHA 2022. The webcast will feature management remarks and present the 6-month results from the SPYRAL HTN-ON MED Randomized Trial. The ON MED data will be presented earlier that day, starting at 3:38 p.m. CST. A press release detailing the ON MED results will also be issued on the same date. A replay of the webcast will be available within 24 hours on Medtronic's investor relations page.
Medtronic plc announced the release of its Fiscal Year 2022 Integrated Performance Report, emphasizing progress in health equity, workforce diversity, and environmental sustainability. Key highlights include:
- Investment of over $69 million for healthcare training, reaching 350,000 medical professionals.
- $2.7 billion invested in R&D.
- Reduction of greenhouse gas emissions intensity by 35%.
The report reflects Medtronic's commitment to its mission of improving health outcomes globally.
Medtronic plc (NYSE: MDT) announced the successful closing of a public offering totaling €3.5 billion in Senior Notes. This includes €500 million of 2.625% Notes due 2025, €1 billion of 3.000% Notes due 2028, €1 billion of 3.125% Notes due 2031, and €1 billion of 3.375% Notes due 2034. The net proceeds, approximately €3.47 billion, will be used to repay maturing senior notes and for general corporate purposes. The offering was managed by leading financial institutions, and all notes are guaranteed by Medtronic plc.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
